WHO Criteria (Systemic Mastocytosis)

Applies the WHO criteria for systemic mastocytosis: one major plus one minor, or three minor.

Open the calculator → Runs in your browser. Data leaves only if you deliberately send a problem report from the interactive tool.

Example

Multifocal dense infiltrates
Yes
Activating KIT mutation
Yes
Measured baseline tryptase, ng/mL
30
Extra alpha-tryptase gene copies
1

Result: Systemic mastocytosis criteria met

The tool opens with these values already filled in. Replace them with your own.

What the result means

The rule
One major criterion plus one minor criterion, or three minor criteria.
Major
Multifocal dense infiltrates of mast cells, 15 or more in aggregates, in bone marrow or another extracutaneous organ.
Minor 1
More than 25 percent of mast cells atypical or spindle-shaped.
Minor 2
An activating KIT point mutation at codon 816 or another critical region.
Minor 3
Mast cells aberrantly expressing CD2, CD25 or CD30. CD30 was admitted in the 2022 edition.
Minor 4
Baseline serum tryptase above 20 ng/mL, only in the absence of an associated myeloid neoplasm.
The correction
In hereditary alpha-tryptasemia, divide the tryptase by 1 plus the EXTRA alpha-tryptase gene copies first. 30 ng/mL with one extra copy corrects to 15 and does NOT meet the criterion.
Why it matters
Where three minor criteria carry the diagnosis, that one item is the difference between systemic and cutaneous mastocytosis.

What you enter

  • Multifocal dense infiltrates
  • Atypical morphology above 25 percent
  • Activating KIT mutation
  • Aberrant CD2, CD25 or CD30
  • Measured baseline tryptase, ng/mL
  • Extra alpha-tryptase gene copies
  • Associated myeloid neoplasm present
How this is calculated

Khoury JD, Solary E, Abla O, et al. The 5th edition of the WHO Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703-1719. Tryptase correction: Valent P, Akin C, Hartmann K, et al, consensus proposal. Read the source ↗

A reference and educational tool. Not medical, legal, or financial advice, and not a substitute for clinician judgment.

Browse all tools

Built by Clay Good. Source on GitHub.